Rottinghaus Scott T.'s Form 4 filing
Enanta Pharmaceuticals Inc (ENTA) · filed Jul 15, 2024
- Accession no.
- 0001062993-24-013820
- Filed
- Jul 15, 2024
- Trade date
- Jul 11-15, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $190.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rottinghaus Scott T.CIK 0001942407 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 11, 2024 | Common Stock | SSaleDisposed | −4,299 | $15.07 | −$64,785.93 | 23,988 | Direct | |
| Jul 12, 2024 | Common Stock | SSaleDisposed | −2,271 | $15.04 | −$34,155.84 | 21,717 | Direct | |
| Jul 15, 2024 | Common Stock | MOption exerciseAcquired | +5,375 | $8.99 | +$48,321.25 | 27,092 | Direct | |
| Jul 15, 2024 | Common Stock | SSaleDisposed | −5,375 | $17.08 | −$91,805 | 21,717 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 15, 2024 | Common Stock | MOption exerciseDisposed | −5,375 | $0.00 | $0 | 80,625 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.